Drug updated on 12/11/2024
| Dosage Form | Injection (subcutaneous/intravenous; 100mg/mL [30 mg/0.3 mL, 40 mg/0.4 mL, 60 mg/0.6 mL, 80 mg/0.8 mL, 100 mg/1 mL, 300 mg/3 mL]); Injection (subcutaneous/intravenous; 150 mg/mL [120 mg/0.8 mL, 150 mg/1 mL]) |
| Drug Class | Low molecular weight heparin (LMWH) |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness
- Indicated for inpatient treatment of acute DVT with or without pulmonary embolism
- Indicated for outpatient treatment of acute DVT without pulmonary embolism
- Indicated for prophylaxis of ischemic complications of unstable angina and nonQ-wave myocardial infarction (MI)
- Indicated for treatment of acute ST-segment elevation myocardial infarction (STEMI) managed medically or with subsequent percutaneous coronary intervention (PCI).
Latest News
Summary
- This summary is based on the review of 19 systematic review(s)/meta-analysis(es). [1-19]
- Factor XI inhibitors reduced thrombotic complications by 50% and bleeding rates by 60% compared to enoxaparin in patients undergoing total knee arthroplasty, indicating a safer and more effective option for this population.
- Fondaparinux and enoxaparin both significantly reduced the risk of deep vein thrombosis (DVT) in trauma patients with hip or lower limb injuries, without an increased bleeding risk compared to placebo, highlighting their effectiveness in this population.
- Desirudin demonstrated a lower incidence of venous thromboembolism (VTE) but was associated with a higher bleeding risk compared to enoxaparin in patients with renal insufficiency, presenting a consideration for higher-risk individuals.
- Rivaroxaban significantly reduced the incidence of VTE and all-cause mortality compared to enoxaparin in orthopedic surgery patients, with no significant difference in major bleeding, supporting its use in surgical contexts.
- Factor XI inhibitors demonstrated lower bleeding rates compared to enoxaparin in knee arthroplasty patients, while desirudin showed a lower risk of VTE but higher bleeding risk in patients with renal insufficiency. For trauma patients with hip or lower limb injuries, both fondaparinux and enoxaparin were effective in preventing DVT without increased bleeding risk. Additionally, apixaban posed a lower risk of major gastrointestinal bleeding compared to enoxaparin and warfarin in thromboembolism management, whereas rivaroxaban increased this bleeding risk.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Lovenox (enoxaparin sodium) Prescribing Information. | 2022 | Sanofi-Aventis U.S. LLC., Bridgewater, NJ |